Zhong X - Search Results

1

HER2-low heterogeneity between primary and paired recurrent/metastatic breast cancer: Implications in treatment and prognosis.

Lin M, Luo T, Jin Y, Zhong X, Zheng D, Zeng C, Guo Q, Wu J, Shao ZM, Hu X, Yang W, Zhang J. Lin M, et al. Among authors: zhong x. Cancer. 2024 Mar 15;130(6):851-862. doi: 10.1002/cncr.35101. Epub 2023 Nov 7. Cancer. 2024. PMID: 37933913

2

Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in a Chinese population.

Luo T, Chen L, He P, Hu QC, Zhong XR, Sun Y, Yang YF, Tian TL, Zheng H. Luo T, et al. Asian Pac J Cancer Prev. 2013;14(4):2433-7. doi: 10.7314/apjcp.2013.14.4.2433. Asian Pac J Cancer Prev. 2013. PMID: 23725153 Free article.

3

[New challenges of personalized therapy for breast cancer to pathologists].

Zhong X, Luo T, Zheng H, Bu H. Zhong X, et al. Zhonghua Bing Li Xue Za Zhi. 2014 Apr;43(4):219-21. Zhonghua Bing Li Xue Za Zhi. 2014. PMID: 24915809 Chinese. No abstract available.

4

Trends and present treatment patterns of early breast cancer in Southwest China.

Hu Q, Luo T, He P, Zhong X, Tian T, Lv Q, Yan X, Zheng H. Hu Q, et al. Among authors: zhong x. Pathol Oncol Res. 2015 Apr;21(2):367-78. doi: 10.1007/s12253-014-9829-z. Epub 2014 Aug 6. Pathol Oncol Res. 2015. PMID: 25096396 Free article.

5

Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.

Deng L, Chen J, Zhong XR, Luo T, Wang YP, Huang HF, Yin LJ, Qiu Y, Bu H, Lv Q, Zheng H. Deng L, et al. PLoS One. 2015 Mar 27;10(3):e0120511. doi: 10.1371/journal.pone.0120511. eCollection 2015. PLoS One. 2015. PMID: 25816324 Free PMC article.

6

Application status of tamoxifen in endocrine therapy for early breast cancer.

Hu Q, Luo T, Zhong X, He P, Tian T, Zheng H. Hu Q, et al. Among authors: zhong x. Exp Ther Med. 2015 Jun;9(6):2207-2212. doi: 10.3892/etm.2015.2437. Epub 2015 Apr 20. Exp Ther Med. 2015. PMID: 26136961 Free PMC article.

7

[Survival of Patients with Metastatic Recurrent Triple-negative Breast Cancer].

Peng ZX, Zhong XR, Wang Z, Wang Y, Wang YP, Zheng H, Jing J. Peng ZX, et al. Sichuan Da Xue Xue Bao Yi Xue Ban. 2016 Jul;47(4):541-546. Sichuan Da Xue Xue Bao Yi Xue Ban. 2016. PMID: 28591958 Chinese.

8

CD49f Can Act as a Biomarker for Local or Distant Recurrence in Breast Cancer.

Ye F, Zhong X, Qiu Y, Yang L, Wei B, Zhang Z, Bu H. Ye F, et al. Among authors: zhong x. J Breast Cancer. 2017 Jun;20(2):142-149. doi: 10.4048/jbc.2017.20.2.142. Epub 2017 Jun 26. J Breast Cancer. 2017. PMID: 28690650 Free PMC article.

9

Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients.

Deng L, Zhu X, Sun Y, Wang J, Zhong X, Li J, Hu M, Zheng H. Deng L, et al. Among authors: zhong x. Cancer Res Treat. 2019 Jan;51(1):128-140. doi: 10.4143/crt.2017.598. Epub 2018 Mar 15. Cancer Res Treat. 2019. PMID: 29540052 Free PMC article.

10

Prognostic nomogram for patients with non-metastatic HER2 positive breast cancer in a prospective cohort.

Luo C, Zhong X, Wang Z, Wang Y, Wang Y, He P, Peng Q, Zheng H. Luo C, et al. Among authors: zhong x. Int J Biol Markers. 2019 Mar;34(1):41-46. doi: 10.1177/1724600818824786. Epub 2019 Mar 11. Int J Biol Markers. 2019. PMID: 30852974 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,588 results

Search Page

Filters